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Therapy of experimental allergic encephalomyelitis under circumstances relevant 
to human multiple sclerosis - Part II 
 
Experimental allergic encephalomyelitis (EAE) is an inflammatory disease of the central 
nervous system (CNS) that resembles human multiple sclerosis (MS). EAE and MS develop when 
proteins of the myelin sheath that covers axons are released and encounter cells of the 
immune system such as T lymphocytes. Activation of these lymphocytes will trigger 
inflammation that destroys the myelin leading to clinical signs that manifest mostly in the 
form of motion impairment and muscle paralysis. Inactivation of myelin specific lymphocytes 
is currently viewed as a means to halt immune attack against the brain and reverse the course 
of disease. Previous research in our lab has shown that peptide delivery on immunoglobulin 
(Ig) is effective against EAE. This method of treatment presents a clinical challenge for use in 
humans, however, because it involves intraperitoneal injection of the chimeric Ig (Ig-MOG). 
We have determined that the oral route, which is more practical, yields comparable results 
against the disease. This model is also useful for investigation of mechanisms of oral 
tolerance. 
